Total, free, and complexed PSA: Analysis and clinical utility

Journal of Clinical Ligand Assay

Volumn 21, Issue 2, 1998, Pages 171-179

  Sokoll, Lori J ^a   Chan, Daniel W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Complexed PSA; Free PSA; Prostate cancer; PSA

Indexed keywords

BIOCHEMICAL MARKER; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; IMMUNOASSAY; PROSTATE CANCER;

EID: 0032450569     PISSN: 10811672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 1998;48:6.
2. Parker SL, Johnston Davis K, Wingo PA, et al: Cancer statistics by race and ethnicity. CA Cancer J Clin 1998;48:31.
3. Rosenthal DS: Changing trends. CA Cancer J Clin 1998;48:49.
4. Wingo PA, Landis S, Ries LAG: An adjustment to the 1997 estimate of new prostate cancer cases. CA Cancer J Clin 1997;47:239.
5. Oestefling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Ural 1991;145:907.
6. Partin AW, Oesterling JE: The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358.
7. Sokoll LJ, Chan DW: Prostate-specific antigen: Its discovery and biochemical characteristics. Urol Clin North Am 1997;24:253.
8. Chan DW, Sokoll LJ: Prostate-specific antigen: update 1997. JIFCC 1997;9:120.
9. Vessella RL, Lange PH: Issues in the assessment of PSA immunoassays. Urol Clin North Am 1993;20:607.
10. McCormack RT, Rittenhouse HG, Finlay JA, et al: Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995;45:729.
11. Christensson A, Laurell CB, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine protease inhibitors. Eur J Biochcm 1990;194:755.
12. 1-antichymotrypsin. J Urol 1996;156:1357.
13. Mikolajczyk SD, Grauer L, Millar LS, et al: A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50:710.
14. Wu JT: Assay for prostate specific antigen (PSA): problems and possible solutions. J Clin Lab Analysis 1994;8:51.
15. Graves HCB: Standardization of immunoassays for prostate-specific antigen. Cancer 1993;72:3141.
16. Participant summary, Ligand assay - general survey 1997 Set K-B. College of American Pathologists 1997:16.
17. Garg UC, Howanitz JH, Nakamura RM, et al: Production, analysis, and characterization of reference materials for prostate-specific antigen. Arch Path Lab Med. 1995;119:1104.
18. Chan DW, Bruzek DJ, Oesterling JE, et al: Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. Clin Chem 1987;33:1916.
19. Stamey TA: Second Stanford conference on international standardization of prostate-specific antigen imraunoassays: September 1 and 2, 1994. Urology 1995;45:173.
20. NCCLS: Purification and characterization of prostate-specific antigen (PSA) and PSA complexed to alpha-1-antichymotrypsin (PSA-ACT) for use as primary standards; proposed guideline. NCCLS Document I/LA 19-P. Villanova, PA, NCCLS, 1994.
21. Graves HCB, Wehner N, Stamey TA: Comparison of a polyclonal and monoclonal assay for PSA: need for an international antigen standard. J Urol 1990;144:1516.
22. Drawer MK, Bankson DD, Haver VM, et al: Comparison of three commercial PSA assays: results of restandardization of the Ciba Corning Method. Prostate 1997;30:269.
23. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214.
24. Woodrum DL, Drawer MK, Partin AW, et al: Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5.
25. Ornstein DK, Smith DS, Rao GS, et al: Biological variation of total free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 1997;157:2179.
26. Nixon RG, Lilly JD, Liedtke RL, et al: Variation of free and total prostate-specific antigen levels. Arch Path Lab Med 1997;121:385.
27. Ornstein DK, Rao GS, Smith DS, et al: Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. J Urol 1997;157:195.
28. Collins GN, Martin PJ, Wynn-Davies A, et al: The effect of digital rectal examination, flexible cystoscopy and prostatic biopsy on free and total prostate specific antigen ratios in clinical practice. J Urol 1997;157:1744.
29. Henchman JD, Smith DS, Catalona WJ: Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology 1997;50:239.
30. Woodrum D, French C, Shamel LB: Stability of free prostate-specific antigen in serum samples under a variety of sample collection and storage conditions. Urology 1996;48(6A):33.
31. Prestigiacomo AF, Stamey TA: Clinical usefulness of free and complexed PSA. Scand J Clin Lab Invest 1995;221:32.
32. Partin AW, Piantadosi S, Subong ENP, et al: Clearance rate of serum-free and total PSA following radical retropubic prostatectomy. Prostate Supp 1996;7:35.
33. Chan DW, Kelley CA, Partin AW, et al: PSA-ACT immunoassay problems and solutions. Clin Chem 1996;42:S255.
34. 1-antichymotrypsin complex. Clin Chem 1995;10:1480.
35. Wang TJ, Linton HJ, Payne J, et al: Development of monoclonal antibodies specific for the PSA-ACT complex and their incorporation into an immunoassay. Clin Chem 1997;43:S225.
36. Zhou AM, Tewari PC, Bluestein BI, et al: Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal antibodies. Clin Chem 1993;39:2483.
37. 2-macroglobulin. Clin Chem 1996;42:545.
38. Yeung KK, Zhou Z, Morris D, et al: Improved specificity in the early detection of prostate cancer using complexed PSA. Tumor Biol 1997;18:100.
39. Pannek J, Partin AW: Prostate-specific antigen: what's new in 1997. Oncology 1997;11:1273.
40. Oesterling JE, Jacobsen SJ, Chute GG, et al: Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270:860.
41. Tchetgen M-BN, Oesterling JE: The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 1997;24:283.
42. Lee CT, Oesterling JE: Diagnostic markers of prostate cancer utility of prostate-specific antigen in diagnosis and staging. Sem Sur One 1995;11:23.
43. Partin AW, Carter HB, Chan DW, et al: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:474.
44. Partin AW, Kattan MW, Subong ENP, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997;277:1445.
45. Vessella RL: Trends in immunoassays of prostate-specific antigen: serum complexes and ultrasensitivity. Clin Chem 1993;39:2035.
46. Stamey TA, Graves HCB, Wehner N, et al: Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J Urol 1993;149:787.
47. Yu H, Diamandis EP, Prestigiacomo AF, et al: Ultrasensitive assay of prostate specific antigen used for early detection of prostate cancer relapse and estimation of tumor doubling time after radical prostatectomy. Clin Chem 1995;41:430.
48. von Eschenbach A, Ho R, Murphy GP, et al: American Cancer Society guidelines for the early detection of prostate cancer. Cancer 1997;80:1805.
49. Carter HB, Epstein JI, Chan DW, et al: Recommended prostate-specific antigen intervals for the detection of curable prostate cancer. JAMA 1997;277:1456.
50. Morgan TO, Jacobsen SJ, McCarthy WF: Age-specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med 1996;335:304.
51. Seaman E, Whang IS, Olsson C, et al: PSA density (PSAD). Role in patient evaluation and management. Urol Clin N Amer 1993;20:653.
52. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215.
53. Stamey TA, Barnhill SD, Zhang Z, et al: Effectiveness of ProstAsure in detecting prostate cancer and benign prostatic hyperplasia in men age 50 or older. J Urol 1996;155:436A.
54. 1-antichymotrypsin. Clin Chem 1991;37:1618.
55. Stenman UH, Leinonen J, Alfthan H, et al: A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222.
56. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100.
57. Stenman U-H: Prostate-specific antigen, clinical use and staging: an overview. Br J Urol 1997;79(Suppl 1):53.
58. Partin AW, Oesterling JE: The clinical usefulness of percent free PSA. Urology 1996;48:1.
59. Luderer AA, Chen YT, Soriano TF, et al: Measurement of the proportion of free to total prostate specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46:187.
60. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214.
61. Partin AW, Catalona WJ, Southwick PC, et al: Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996;48(6A):55.
62. Catalona WJ, Smith DS, Omstein DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. JAMA 1997;277:1452.
63. Vashi AR, Wojno KJ, Henricks W, et al: Determination of the reflex range and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997;49:19.
64. Partin AW, Carter HB: The use of prostate-specific antigen and free/ total prostate-specific antigen in the diagnosis of localized prostate cancer. Urol Clin North Am 1996;23:531.
65. Bangma C, Kranse R, Blijenberg BG, et al: The value of screening tests in the detection of prostate cancer. Part 1: results of a retrospective evaluation of 1726 men. Urol 1995;46:773.
66. Chen Y-T, Luderer AA, Thiel RP, et al: Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urol 1996;47:518.
67. Prestigiacomo AF, Lilj a H, Pettersson K, et al: A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostate: the best case scenario. J Urol 1996;156:350.
68. Marley GM, Miller MC, Kattan MW, et al: Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urol 1009;48(6A):16.
69. Roehrbom CG, Gregory A, McConnell JD, et al: Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. Urol 1996;48(6A):23.
70. Thiel RP, Oesterling JE, Wojno KJ, et al: Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urol 1996;48(6A):45.
71. Reissigl A, Klocker H, Pointner J, et al: Usefulness of the ratio free/ total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urol 1996;48(6A):62.
72. Van Cangh PJ, De Nayer P, De Vischer L, et al: Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 μg/L total PSA. Urol 1996;48(6A):67.
73. Sokoll LJ, Jones KA, Kelley CA, et al: Clinical evaluation of three free prostate specific antigen (PSA) assays in combination with different total PSA assays. Clin Chem 1997;43:S221.
74. Arcangeli CG, Shepherd DL, Smith DL, et al: Correlation of percent free PSA with pathologic features of prostatic carcinoma. J Urol 1996;155:415A.
75. Pannek J, Subong ENP, Jones KA, et al: The role of free/total prostate specific antigen ratios in the prediction of final pathological stage for men with clinically localized prostate cancer. Urology 1996;48(6A):51.
76. Carter HB, Partin AW, Luderer AA, et al: Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 1997;49:379.
77. Oesterling JE, Chan DW, Epstein JI, et al: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766.
78. Stamey TA, Yang N, Hay AR, et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909.
79. Richardson TD, Wojno KJ, Liang LW: Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy. Urology 1996;48(6A):40.
80. Pannek J, Marks LS, Pearson JD, et al: Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 1998;159:449.
81. Bjork T, Piironen T, Pettersson K, et al: Comparison of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 1996;48:882.
82. Sokoll LJ, Bruzek DJ, Cox JL, et al: Is complexed PSA clinically useful? J Urol 1998;159:234 (abstract).